Oculus Innovative Sciences (OCLS) Announces U.S. Launch of Lasercyn
- Wall St opens flat ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Oculus Innovative Sciences Launches Lasercynâ„¢ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
August 30, 2016 4:05 AM EDTPETALUMA, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the commercial launch into the U.S. dermatology market of the companys newest dermatology product, Lasercyn. Under the supervision of a healthcare professional, Lasercyn is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.
Dr. Michael Gold,... More